Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

52.03 -1.03 (-1.94%)
Streaming Delayed Price Updated: 10:38 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Cathie Wood's Flagship ARK ETF Marks 5-Day Winning Streak — Outperforming Nasdaq, FAANG In May
Cathie Wood's flagship fund Ark Innovation ETF (ARCA: ARKK) marked a five-day winning streak on Wednesday for the first time since January, as a lower-than-expected U.S. 
Via Benzinga
Expert Ratings for Exact Sciences
Via Benzinga
Why Shares of Exact Sciences Rose on Wednesday
The diagnostic testing company announced strong first-quarter earnings. 
Via The Motley Fool
Exact Sciences Guidance Beat Street View, Analyst Says Company Fires All Cylinders
Exact Sciences Corp's (NASDAQ: EXAS) Q1 revenues increased 24% Y/Y to $602 million, beating the average Wall Street esti 
Via Benzinga
Upstart, Compass, RingCentral And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones dropping around 70 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Exact Sciences (EXAS) Q1 2023 Earnings Call Transcript
EXAS earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Analyst Ratings for Exact Sciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
A New Groundbreaking Tool to Detect Colon Cancer Earlier
A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... 
Via PressReach
Exposures Product Safety
EXAS Stock Earnings: Exact Sciences Beats EPS, Revenue Estimates
EXAS stock posted Q1 results that include a loss per share of 42 cents and revenue that was much better than analysts expected. 
Via InvestorPlace
Exact Sciences Posts Its 11th Consecutive Sales Beat As It Targets 'The Most Preventable' Cancer
The company sells Cologuard, a test to screen for colon cancer. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023
Via Benzinga
3 Stocks That AI Predicts Will Outperform the Market
Here are three stocks that came up when I asked the generative AI chatbot that powers Bing chat to make some AI stock recommendations 
Via InvestorPlace
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Exposures Artificial Intelligence Death Product Safety
The 7 Best Biotech Stocks for Personalized Medicine Investors
Personalized Medicine Stocks Promise to Make Healthcare More Individualized with therapeutics based on individual genetics. 
Via InvestorPlace
Cathie Wood’s Next Big Bet: 3 Disruptive Innovations to Watch
These Cathie Wood stocks could deliver massive gains in the coming years as they disrupt traditional industries. 
Via InvestorPlace
What Has Cathie Wood Been Trading?
The story of Ark Invest, Wall Street veteran Cathie Wood’s lineup of actively managed, innovation-centric ETFs is well-known at this point. Ark has been defined by big bets, big wins, big losses, and... 
Via Benzinga
2 Supercharged Growth Stocks That Could Rocket 116% to 899% Higher, According to Wall Street
Find out why expectations are so high for these two innovative businesses. 
Via The Motley Fool
The 3 Best Millionaire-Maker Stocks to Buy for April 2023
These millionaire-maker stocks certainly have the growth profiles to help investors reach their goals of becoming a millionaire. 
Via InvestorPlace
3 Cathie Wood Stocks for Your April Must-Buy List
Cathie Wood stocks are doing much better in 2023 than last year. Here are three to put on your April must-buy list. 
Via InvestorPlace
FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle
The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell. 
Via Investor's Business Daily
3 Stocks With Superior Potential for Super-Sized Gains in 2023
Investing in stocks with potential is a great way to make money as long as you do your research and understand the risks involved. 
Via InvestorPlace
If You Invested $10,000 in Exact Sciences in 2018, This Is How Much You Would Have Today
Has this been a market-beating investment? 
Via The Motley Fool
EXAS Stock Is a Hidden Gem in the Healthcare Sector for Bold Investors
Patient investors who have room for an intriguing medical-niche investment in their portfolio should take a closer look at EXAS stock. 
Via InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday
Credit Suisse cut the price target for Zscaler, Inc. (NASDAQ: ZS) from $275 to $165. Credit Suisse analyst Sami Badri maintained an Outperform rating. Zscaler shares fell 1.9% to $105.95 in pre-market... 
Via Benzinga
7 Growth Stocks Sitting in a Sweet Spot
Offering ample growth potential, and each attractively-priced, now's the time to buy these seven growth stocks. 
Via InvestorPlace
A Nasdaq Bull Market Is Coming: 2 Revolutionary Stocks to Buy and Hold
It pays to be an innovator. 
Via The Motley Fool
What You Missed On Wall Street On Thursday
SVB Financial is lower after the company announced it was undertaking a strategic repositioning of its balance sheet and also provided a negative update to both Q1 and full-year 2023 guidance. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.